Corona vaccine material benefit: This is what Pfizer and Moderna will generate in revenues in 2021

New York, USA (CNN) – There is no doubt that the imminent licensing of the Coronavirus vaccine around the world is a very important occasion for science, economics and humanity .. However, we must not forget that it is also a major source of revenue for the companies that developed these vaccines.

Wall Street analysts expect Pfizer and Moderna to generate $ 32 billion in revenue from the Coronavirus vaccine next year alone.

These analyzes do not take into account the push these companies will get to help them end the worst pandemic of this century, a boost inflated for Moderna, a startup biotechnology company few people have heard of before 2020, and which may now be on the verge of Obtaining its own license from the US Food and Drug Administration.

Pfizer alone is expected to generate $ 19 billion in revenue from the Corona vaccine in 2021, according to Morgan Stanley, in addition to the vaccine revenues estimated at $ 975 million in 2020.

Pfizer will share revenue with “BioNTech”, the German company that has partnered with it to develop the vaccine. On Thursday, a panel of US Food and Drug Administration advisers recommended that the agency grant permission for emergency use of the candidate vaccine developed by the two companies. US officials said they were working “quickly” to give the vaccine a green light.

The Pfizer vaccine actually got a license in the UK earlier this month.

Pfizer is expected to receive an additional $ 9.3 billion from the proceeds of the Corona virus vaccine in 2022 and 2023 as the world continues to be vaccinated, according to Morgan Stanley.

The vaccine breakthrough did not spark a price spike in Pfizer because the drugmaker is already huge, with Pfizer stock up just 12% this year, narrowly behind the S&P 500’s overall gain of 13.5%.

Even so, Pfizer’s expected revenue generation in 2021 will significantly exceed the company’s best-selling product from last year, a pneumonia vaccine that has achieved sales of $ 5.8 billion.

In contrast, Moderna’s Corona Vaccine Candidate has transformed an almost unknown company into a powerhouse with revenues of $ 62 billion, as stocks have risen nearly 700% this year, and Morgan Stanley estimates that about half of the company’s market value is related to the vaccine.

Moderna is expected to reap $ 13.2 billion from the proceeds of the Corona vaccine next year, according to Goldman Sachs, while Morgan Stanley said that Moderna’s high share price indicates that investors expect the company to achieve between 10 billion. $ 15 billion in corona vaccine sales in 2021 and 2022, followed by sales of another billions.